- Home
- MIRM vs SSL Comparison
MIRM vs SSL Comparison
Compare MIRM & SSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- SSL
- Stock Information
- Founded
- MIRM 2018
- SSL 1950
- Country
- MIRM United States
- SSL South Africa
- Employees
- MIRM 349
- SSL N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- SSL Oil & Gas Production
- Sector
- MIRM Health Care
- SSL Energy
- Exchange
- MIRM Nasdaq
- SSL Nasdaq
- Market Cap
- MIRM 3.7B
- SSL 4.0B
- IPO Year
- MIRM 2019
- SSL N/A
- Fundamental
- Price
- MIRM $72.85
- SSL $5.97
- Analyst Decision
- MIRM Strong Buy
- SSL
- Analyst Count
- MIRM 11
- SSL 0
- Target Price
- MIRM $76.09
- SSL N/A
- AVG Volume (30 Days)
- MIRM 712.9K
- SSL 1.2M
- Earning Date
- MIRM 11-11-2025
- SSL 01-01-0001
- Dividend Yield
- MIRM N/A
- SSL N/A
- EPS Growth
- MIRM N/A
- SSL N/A
- EPS
- MIRM N/A
- SSL 0.59
- Revenue
- MIRM $429,161,000.00
- SSL $14,028,282,389.00
- Revenue This Year
- MIRM $53.14
- SSL N/A
- Revenue Next Year
- MIRM $19.83
- SSL $5.73
- P/E Ratio
- MIRM N/A
- SSL $10.13
- Revenue Growth
- MIRM 62.33
- SSL N/A
- 52 Week Low
- MIRM $36.88
- SSL $2.78
- 52 Week High
- MIRM $78.10
- SSL $7.25
- Technical
- Relative Strength Index (RSI)
- MIRM 56.46
- SSL 36.34
- Support Level
- MIRM $70.49
- SSL $6.11
- Resistance Level
- MIRM $74.96
- SSL $6.25
- Average True Range (ATR)
- MIRM 1.82
- SSL 0.12
- MACD
- MIRM -0.72
- SSL -0.08
- Stochastic Oscillator
- MIRM 51.03
- SSL 2.05
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About SSL Sasol Ltd.
Sasol Ltd operates as a vertically integrated chemicals and energy company through its two main businesses: Southern Africa Energy & Chemicals business; and International Chemical business. It generates maximum revenue from the Southern Africa Energy & Chemicals business. The company operates coal mines and its upstream interests in oil and gas, both of which are used as feedstock in the company's energy and chemicals operations. Geographically the company generates the majority of its revenue from South Africa.